mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression
Year: 2026
Type: article
Abstract: Proteins encoded by mRNA vaccines can be expressed by a diversity of transfected cell types but how cell-type-specific expression influences immunity is poorly understood. To investigate this, we incorporated synthetic microRNA target sites (miRT) into lipid nanoparticle (LNP)-delivered mRNA vaccines to silence mRNA expression specifically in professional antigen-presenting cells (pAPCs), hepatocytes or myocytes. We found that mRNA expression in pAPCs was dispensable for priming antigen-specific T cells, whereas mRNA expression in myocytes induced similar or stronger immune responses, including for SARS-CoV-2, suggesting that antigen cross-presentation or cross-dressing may be more impactful than direct mRNA expression in pAPCs. In contrast, mRNA expression in hepatocytes suppressed the antigen-specific T cell response, partly through PD1/PDL1. In mice bearing tumor-associated antigen (TAA)-expressing lymphoma cells, miRT-mediated hepatocyte-silenced TAA mRNA vaccine enhanced immune response and reduced tumor burden. Thus, non-pAPC expression shapes immunity to mRNA-encoded protein and inclusion of miRTs can boost or blunt mRNA-LNP immunogenicity.
Source: Nature Biotechnology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
Awards: G2354209684, G5914036706, G6817353502, Development of novel lipid nanoparticles for nucleic acids delivery in the brain, microRNA-controlled mRNA therapeutics, Deciphering the molecular control of intratumoral dendritic cells, Hepatocytes and skeletal myocytes shape immunity to mRNA-LNP encoded protein, Translational Immunology Training Program
OpenAlex ID: W7158998328
